Weight Loss
Wegovy®
A once-weekly semaglutide injection, FDA-approved for chronic weight management and to reduce cardiovascular event risk in eligible adults.
Price is based on patient insurance and pharmacy collection
*Requires a Mochi Health Membership. Cost of medication not included in Mochi Health Membership Fee
Results
Treatment overview
FDA-Approved Therapy
1
Wegovy is FDA-approved for weight management.
Proven Weight Loss
2
Clinical trials showed average weight loss of about 15% of body weight with Wegovy.
Reduced Appetite
3
Curbs hunger and food cravings, making it easier to stick to a healthy eating plan.
Cardiovascular Risk Reduction
4
FDA-approved to reduce the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with established cardiovascular disease and obesity or overweight.
Gradual Dose Titration
5
Started at a low dose and increased gradually over months to help your body adjust.
Once-Weekly Pen
6
Pre-filled, easy-to-use pen taken once weekly on the same day each week.
The treatment
Understanding the treatment
Active Ingredient:
Semaglutide
Wegovy is a once-weekly injectable GLP-1 receptor agonist that mimics a natural gut hormone to reduce appetite and slow stomach emptying. It is FDA-approved for chronic weight management in adults with obesity, or overweight with at least one weight-related comorbid condition, and to reduce the risk of major cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) in adults with established cardiovascular disease and obesity or overweight. Dosing is titrated gradually upward over several months to minimize gastrointestinal side effects and reach the therapeutic dose.
Side effects
Most common: nausea, vomiting, diarrhea, constipation, abdominal discomfort, headache, fatigue, injection-site reactions. Less common but serious: pancreatitis, gallbladder disease, kidney injury, hypoglycemia (with other diabetes meds), diabetic retinopathy progression, and rare allergic reactions.
Avoid When
Personal or family history of medullary thyroid cancer or MEN 2; history of pancreatitis; severe GI disease including gastroparesis; pregnancy or breastfeeding; known hypersensitivity. Caution with insulin/sulfonylureas, gallbladder disease, diabetic retinopathy, and significant kidney disease.
Personalized care
The medication is
the smaller part
Mochi pairs you with a physician, care team, pharmacist, and personalized plan designed to support your body, progress, and long-term goals over time.
For iOS & Android
